KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Co-Diagnostics (CODX) Equity Ratio (2017 - 2025)

Historic Equity Ratio for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to 0.89.

  • Co-Diagnostics' Equity Ratio rose 101.88% to 0.89 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.89, marking a year-over-year increase of 101.88%. This contributed to the annual value of 0.85 for FY2024, which is 595.5% down from last year.
  • According to the latest figures from Q3 2025, Co-Diagnostics' Equity Ratio is 0.89, which was up 101.88% from 0.89 recorded in Q2 2025.
  • Co-Diagnostics' 5-year Equity Ratio high stood at 0.95 for Q3 2021, and its period low was 0.84 during Q4 2021.
  • Its 5-year average for Equity Ratio is 0.9, with a median of 0.9 in 2023.
  • In the last 5 years, Co-Diagnostics' Equity Ratio plummeted by 1025.04% in 2021 and then skyrocketed by 1072.43% in 2022.
  • Quarter analysis of 5 years shows Co-Diagnostics' Equity Ratio stood at 0.84 in 2021, then grew by 10.72% to 0.93 in 2022, then decreased by 3.01% to 0.9 in 2023, then fell by 5.96% to 0.85 in 2024, then increased by 4.9% to 0.89 in 2025.
  • Its Equity Ratio stands at 0.89 for Q3 2025, versus 0.89 for Q2 2025 and 0.87 for Q1 2025.